EGFR and non-small cell lung carcinoma: However, for most patients with early-stage NSCLC who have EGFR wild-type tumors, standard adjuvant chemotherapy (10, 11) resulted in only a 4-5% improvement in the 5-year survival rate compared with that of surgery alone (12, 13).